Zymeworks (ZYME)
(Real Time Quote from BATS)
$14.92 USD
+0.25 (1.70%)
Updated Jan 23, 2025 03:44 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZYME 14.92 +0.25(1.70%)
Will ZYME be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for ZYME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZYME
Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 41.36%: Here's is How to Trade
Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates
ZYME: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK (GSK) Q3 Earnings Surpass Estimates
Zymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue Estimates
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Other News for ZYME
12 Health Care Stocks Moving In Thursday's Pre-Market Session
3 Biotech Stocks With Notable Insider Buying
EcoR1 Capital, LLC Expands Stake in Zymeworks Inc with Strategic Acquisition
EcoR1 Capital, LLC Increases Stake in Zymeworks Inc
EcoR1 Capital, LLC Expands Stake in Zymeworks Inc with Strategic Acquisition